Michel Kindo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michel Kindo has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
Jean-Philippe Mazzucotelli
Department of Cardiac Surgery, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
22 shared publicationsTam Hoang Minh
13 shared publicationsPhilippe Billaud
11 shared publicationsStéphanie Perrier
Department of Cardiovascular Surgery, University Hospitals of Strasbourg, Strasbourg, France
11 shared publicationsClément Schneider
9 shared publications- Patrick Ohlmann
Department of Cardiology, Strasbourg University Hospital, Strasbourg, France
9 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Elsevier in JTCVS Open
External validation of the Society of Thoracic Surgeons Ascending Aorta & Aortic Root Surgery Risk Calculator in a French cohort
- 5 October 2026
- Published by Elsevier in JTCVS Open
Open AccessExternal validation of the Society of Thoracic Surgeons Ascending Aorta & Aortic Root Surgery Risk Calculator in a French cohort
- Open Access
- 23 September 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 480
Altered Peripheral Blood Mononuclear Cell (PBMC) Mitochondrial Coupling and Complex IV Respiration in Severe Aortic Stenosis Before and After Transcatheter Aortic Valve Replacement (TAVR)
Background: Circulating peripheral blood mononuclear cell (PBMC) mitochondrial respiration is impaired in heart failure and transplanted patients. Severe aortic stenosis (AS), characterized by pressure overload leading to cardiac mitochondrial dysfunction, might also be associated with PBMC mitochondrial respiration alterations, likely related to systemic inflammation and left heart hypertrophy and diastolic dysfunction. Population and Methods: We determined PBMC mitochondrial respiration by high-resolution respirometry (Oroboros Instruments) in 9 healthy subjects and 25 AS patients before and until 30 days after transcatheter aortic valve replacement (TAVR) and investigated potential correlates with the clinical, biological and echocardiographic characteristics of the patients. Results: AS patients with a transaortic valvular gradient of 45 mm Hg were older and demonstrated slightly impaired renal function, inflammation markers, increased brain natriuretic peptide, left ventricular hypertrophy, and impaired diastolic function. PBMC mitochondrial coupling was decreased in the AS patients compared to controls (2.12 ± 0.10 vs. 2.76 ± 0.17, p = 0.003) and mitochondrial complex IV respiration was increased (31.07 ± 2.84 vs. 18.69 ± 2.09, p = 0.017). TAVR did not modify the alterations. Interestingly, increased complex IV mitochondrial respiration was associated with reduced mortality (p < 0.01). Conclusions: Severe aortic stenosis is associated with bioenergetic remodeling of circulating mononuclear cells that were not significantly associated with valvular hemodynamic impairment and ventricular function, before and after the mechanical relief of afterload. Nevertheless, future studies will be useful to determine whether such systemic immuno-metabolic phenotype, particularly PBMC mitochondrial complex IV respiration stimulation, may contribute to reduce the risk following TAVR.
- 23 September 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 480
Open AccessAltered Peripheral Blood Mononuclear Cell (PBMC) Mitochondrial Coupling and Complex IV Respiration in Severe Aortic Stenosis Before and After Transcatheter Aortic Valve Replacement (TAVR)
Background: Circulating peripheral blood mononuclear cell (PBMC) mitochondrial respiration is impaired in heart failure and transplanted patients. Severe aortic stenosis (AS), characterized by pressure overload leading to cardiac mitochondrial dysfunction, might also be associated with PBMC mitochondrial respiration alterations, likely related to systemic inflammation and left heart hypertrophy and diastolic dysfunction. Population and Methods: We determined PBMC mitochondrial respiration by high-resolution respirometry (Oroboros Instruments) in 9 healthy subjects and 25 AS patients before and until 30 days after transcatheter aortic valve replacement (TAVR) and investigated potential correlates with the clinical, biological and echocardiographic characteristics of the patients. Results: AS patients with a transaortic valvular gradient of 45 mm Hg were older and demonstrated slightly impaired renal function, inflammation markers, increased brain natriuretic peptide, left ventricular hypertrophy, and impaired diastolic function. PBMC mitochondrial coupling was decreased in the AS patients compared to controls (2.12 ± 0.10 vs. 2.76 ± 0.17, p = 0.003) and mitochondrial complex IV respiration was increased (31.07 ± 2.84 vs. 18.69 ± 2.09, p = 0.017). TAVR did not modify the alterations. Interestingly, increased complex IV mitochondrial respiration was associated with reduced mortality (p < 0.01). Conclusions: Severe aortic stenosis is associated with bioenergetic remodeling of circulating mononuclear cells that were not significantly associated with valvular hemodynamic impairment and ventricular function, before and after the mechanical relief of afterload. Nevertheless, future studies will be useful to determine whether such systemic immuno-metabolic phenotype, particularly PBMC mitochondrial complex IV respiration stimulation, may contribute to reduce the risk following TAVR.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Auto-regulated bioprosthetic total artificial heart as bridge to transplantation: the EFICAS study
Background and Aims: Refractory advanced biventricular heart failure (RAHF) has a poor prognosis, and many patients are ineligible for left ventricular assist device (LVAD) support. The ‘historical’ total artificial heart (TAH) is associated with high rates of stroke, bleeding, and haemolysis. The bioprosthetic TAH (bio-TAH), a pulsatile, auto-regulated, and haemocompatible device, was assessed here as a bridge to transplantation. Methods: EFICAS (NCT04475393) was a prospective, multi-centre trial conducted at 10 French centres. Adults with RAHF who were ineligible for LVAD support and listed or eligible for heart transplantation were enrolled. The primary composite endpoint was survival at 180 days free from disabling stroke, device malfunction requiring reoperation or urgent transplantation, or elective heart transplantation. Secondary endpoints included serious adverse events, New York Heart Association (NYHA) class, the 6-min walk test, and quality-of-life measured using the EQ-5D-5L. Results: Fifty-five patients underwent implantation (December 2022 and May 2025; median age, 56 years [IQR, 48–63]; 49% INTERMACS profiles 1–2; 36% on venoarterial extracorporeal membrane oxygenation). The primary endpoint was achieved in 40 patients (72.7%; 95% confidence interval, 57.1–85.1), exceeding the pre-specified ‘historical TAH’ threshold of 38% (P < .0001). At 180 days, 96% were free of disabling stroke, 76% were discharged, and 92% were NYHA class I-II. Median 6-minute walk distance improved by 305 m (P = .0002) and EQ-5D by 40 points (P < .0001). No haemolysis occurred, and major bleeding was limited to the first 30 days. Conclusions: The bio-TAH achieved its primary endpoint with a favourable safety profile, supporting its use as an effective bridge-to-transplant strategy in patients with RAHF ineligible for LVAD support.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Auto-regulated bioprosthetic total artificial heart as bridge to transplantation: the EFICAS study
Background and Aims: Refractory advanced biventricular heart failure (RAHF) has a poor prognosis, and many patients are ineligible for left ventricular assist device (LVAD) support. The ‘historical’ total artificial heart (TAH) is associated with high rates of stroke, bleeding, and haemolysis. The bioprosthetic TAH (bio-TAH), a pulsatile, auto-regulated, and haemocompatible device, was assessed here as a bridge to transplantation. Methods: EFICAS (NCT04475393) was a prospective, multi-centre trial conducted at 10 French centres. Adults with RAHF who were ineligible for LVAD support and listed or eligible for heart transplantation were enrolled. The primary composite endpoint was survival at 180 days free from disabling stroke, device malfunction requiring reoperation or urgent transplantation, or elective heart transplantation. Secondary endpoints included serious adverse events, New York Heart Association (NYHA) class, the 6-min walk test, and quality-of-life measured using the EQ-5D-5L. Results: Fifty-five patients underwent implantation (December 2022 and May 2025; median age, 56 years [IQR, 48–63]; 49% INTERMACS profiles 1–2; 36% on venoarterial extracorporeal membrane oxygenation). The primary endpoint was achieved in 40 patients (72.7%; 95% confidence interval, 57.1–85.1), exceeding the pre-specified ‘historical TAH’ threshold of 38% (P < .0001). At 180 days, 96% were free of disabling stroke, 76% were discharged, and 92% were NYHA class I-II. Median 6-minute walk distance improved by 305 m (P = .0002) and EQ-5D by 40 points (P < .0001). No haemolysis occurred, and major bleeding was limited to the first 30 days. Conclusions: The bio-TAH achieved its primary endpoint with a favourable safety profile, supporting its use as an effective bridge-to-transplant strategy in patients with RAHF ineligible for LVAD support.
- Open Access
- 9 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7113
Femoral Closure with Single ProGlide® in Transcatheter Aortic Valve Implantation: A Registry-Based Study
Background: Vascular closure of the femoral artery during transcatheter aortic valve implantation (TAVI) remains a critical step prone to complications, despite advancements in introducer technology. The traditional technique involves using two ProGlide® suture closure devices (2P), but alternative approaches, such as employing a single ProGlide® device (1P), have emerged. Aims: We sought to evaluate the efficacy and safety of the 1P strategy compared to the standard 2P closure technique during transfemoral TAVI procedures. Methods: A registry-based study was conducted at the University Hospitals of Strasbourg, France, from January 2020 to December 2023. Consecutive patients who underwent TAVI via the transfemoral approach were deemed eligible. Results: The study cohort consisted of 1303 patients, with a mean age of 81.7 years and 47% female. The 1P strategy was used in 733 cases (56.3%), while the 2P technique was employed in 570 patients (43.7%). Hemostasis was achieved in the catheterization laboratory without additional devices in 30.4% of the single-ProGlide® pre-closing cases. Vascular complication rates were similar in both groups, at 11.3% for the 1P technique and 11.4% for the 2P technique (p = 0.964). However, vascular closure device failure was significantly less frequent in the 1P group (1.6%) compared to the 2P group (5.3%). Conclusions: The 1P strategy for pre-closing during TAVI is as effective and safe as the conventional 2P approach. The 1P method offers potential advantages in terms of simplicity and cost-effectiveness.
- 9 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7113
Open AccessFemoral Closure with Single ProGlide® in Transcatheter Aortic Valve Implantation: A Registry-Based Study
Background: Vascular closure of the femoral artery during transcatheter aortic valve implantation (TAVI) remains a critical step prone to complications, despite advancements in introducer technology. The traditional technique involves using two ProGlide® suture closure devices (2P), but alternative approaches, such as employing a single ProGlide® device (1P), have emerged. Aims: We sought to evaluate the efficacy and safety of the 1P strategy compared to the standard 2P closure technique during transfemoral TAVI procedures. Methods: A registry-based study was conducted at the University Hospitals of Strasbourg, France, from January 2020 to December 2023. Consecutive patients who underwent TAVI via the transfemoral approach were deemed eligible. Results: The study cohort consisted of 1303 patients, with a mean age of 81.7 years and 47% female. The 1P strategy was used in 733 cases (56.3%), while the 2P technique was employed in 570 patients (43.7%). Hemostasis was achieved in the catheterization laboratory without additional devices in 30.4% of the single-ProGlide® pre-closing cases. Vascular complication rates were similar in both groups, at 11.3% for the 1P technique and 11.4% for the 2P technique (p = 0.964). However, vascular closure device failure was significantly less frequent in the 1P group (1.6%) compared to the 2P group (5.3%). Conclusions: The 1P strategy for pre-closing during TAVI is as effective and safe as the conventional 2P approach. The 1P method offers potential advantages in terms of simplicity and cost-effectiveness.
- 25 July 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (3) , 671-680.e4
Optimizing patient blood management through intraoperative goal-directed fluid therapy protocol within an enhanced recovery after cardiac surgery program
- 25 July 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (3) , 671-680.e4
Optimizing patient blood management through intraoperative goal-directed fluid therapy protocol within an enhanced recovery after cardiac surgery program
- 7 July 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 177-184.e2
Coronary revascularization in France: Six-year trends and outcomes in coronary artery bypass grafting and percutaneous coronary intervention
- 7 July 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 177-184.e2
Coronary revascularization in France: Six-year trends and outcomes in coronary artery bypass grafting and percutaneous coronary intervention
- Open Access
- 26 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 800
Transpulmonary LOX-1 Levels Are Predictive of Acute Respiratory Distress Syndrome After Cardiac Surgery: A Proof-of-Concept Study
Background/Objectives: Acute respiratory distress syndrome (ARDS) is a life-threatening condition that frequently complicates high-risk cardiac surgery. We evaluated the circulating levels and transpulmonary gradient of intracellular proteins in patients at risk of developing ARDS after cardiac surgery using large scale-proteomics. Methods: We enrolled sixteen patients undergoing high-risk cardiac surgery, followed by planned ICU admission. Circulating levels of intracellular proteins were measured at the onset of the surgical procedure, at ICU admission (H0), and 24 h (H24) after surgery in blood samples simultaneously drawn from both the pulmonary artery and the left atrium. The primary endpoint was the occurrence of ARDS between ICU admission and the subsequent 48 h. Results: Among the studied proteins, the levels of intracellular lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) were higher at H24 in the pulmonary artery in patients who developed ARDS (6.96; 95% CI [6.83–7.23]) compared to patients who did not (6.48; 95% CI [6.27–6.66]), p-value = 0.016. The transpulmonary gradient of intracellular LOX-1 levels was not significantly different between ARDS and non-ARDS patients at H0 but it was more negative at H24 in ARDS (−0.23; 95% CI [−0.27, −0.14]) than in non-ARDS patients (0.03; 95% CI [−0.14, 0.32]; p-value= 0.031), with a hazard ratio HR = 0.39 (95% CI [0.18–0.86]); p-value= 0.035. The area under the ROC curve of H24 LOX-1 transpulmonary gradient to predict ARDS occurrence was 0.83 (95% CI [0.62–1.00]). Conclusions: The transpulmonary gradient of intracellular LOX-1 levels was negatively associated with the occurrence of ARDS within the first 48 h after high-risk cardiac surgery, suggesting that lung trapping of LOX-1 may be linked to postoperative ARDS.
- 26 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 800
Open AccessTranspulmonary LOX-1 Levels Are Predictive of Acute Respiratory Distress Syndrome After Cardiac Surgery: A Proof-of-Concept Study
Background/Objectives: Acute respiratory distress syndrome (ARDS) is a life-threatening condition that frequently complicates high-risk cardiac surgery. We evaluated the circulating levels and transpulmonary gradient of intracellular proteins in patients at risk of developing ARDS after cardiac surgery using large scale-proteomics. Methods: We enrolled sixteen patients undergoing high-risk cardiac surgery, followed by planned ICU admission. Circulating levels of intracellular proteins were measured at the onset of the surgical procedure, at ICU admission (H0), and 24 h (H24) after surgery in blood samples simultaneously drawn from both the pulmonary artery and the left atrium. The primary endpoint was the occurrence of ARDS between ICU admission and the subsequent 48 h. Results: Among the studied proteins, the levels of intracellular lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) were higher at H24 in the pulmonary artery in patients who developed ARDS (6.96; 95% CI [6.83–7.23]) compared to patients who did not (6.48; 95% CI [6.27–6.66]), p-value = 0.016. The transpulmonary gradient of intracellular LOX-1 levels was not significantly different between ARDS and non-ARDS patients at H0 but it was more negative at H24 in ARDS (−0.23; 95% CI [−0.27, −0.14]) than in non-ARDS patients (0.03; 95% CI [−0.14, 0.32]; p-value= 0.031), with a hazard ratio HR = 0.39 (95% CI [0.18–0.86]); p-value= 0.035. The area under the ROC curve of H24 LOX-1 transpulmonary gradient to predict ARDS occurrence was 0.83 (95% CI [0.62–1.00]). Conclusions: The transpulmonary gradient of intracellular LOX-1 levels was negatively associated with the occurrence of ARDS within the first 48 h after high-risk cardiac surgery, suggesting that lung trapping of LOX-1 may be linked to postoperative ARDS.
- Open Access
- 14 March 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (3)
Contribution of cardiac surgeons in transcatheter aortic valve replacement activity in France
OBJECTIVES: This study provides a thorough analysis of cardiac surgeons' involvement in transcatheter aortic valve replacement (TAVR) activities in France, covering decision-making, procedural roles, training, and outcome analysis. METHODS: A nationwide survey was sent to all cardiac surgeons and all cardiac surgery trainees in France. Subgroup analysis was performed for age, status (established versus in-training), and type of practice facility. RESULTS: A total of 172 surgeons from both private and public sectors responded to the survey. Most respondents, 71%, had TAVR activity, and there were no significant differences between subgroups. Most respondents with TAVR activities, 30%, had average access (once per week). Almost one-third of centers had >3 established surgeons with TAVR activity, whereas 19% had no in-training surgeons with TAVR activity. TAVR was the only structural practice for 67% of surgeons, while 33% practiced other structural procedures. When asked, 82% of surgeons were against establishing TAVR programs in centers without a cardiac surgery program. Most TAVR patients, 72%, were discussed by the Heart Team, and only 9% of surgeons said their relationship with the interventional cardiologist was disrupted. Two-thirds of vascular complications were managed by cardiac surgery, and only 6% of cardiac surgeons admitted were unfit to handle any vascular complications. CONCLUSIONS: In France, cardiac surgeons are becoming increasingly involved in TAVR procedures as an integral part of the Heart Team.
- 14 March 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (3)
Open AccessContribution of cardiac surgeons in transcatheter aortic valve replacement activity in France
OBJECTIVES: This study provides a thorough analysis of cardiac surgeons' involvement in transcatheter aortic valve replacement (TAVR) activities in France, covering decision-making, procedural roles, training, and outcome analysis. METHODS: A nationwide survey was sent to all cardiac surgeons and all cardiac surgery trainees in France. Subgroup analysis was performed for age, status (established versus in-training), and type of practice facility. RESULTS: A total of 172 surgeons from both private and public sectors responded to the survey. Most respondents, 71%, had TAVR activity, and there were no significant differences between subgroups. Most respondents with TAVR activities, 30%, had average access (once per week). Almost one-third of centers had >3 established surgeons with TAVR activity, whereas 19% had no in-training surgeons with TAVR activity. TAVR was the only structural practice for 67% of surgeons, while 33% practiced other structural procedures. When asked, 82% of surgeons were against establishing TAVR programs in centers without a cardiac surgery program. Most TAVR patients, 72%, were discussed by the Heart Team, and only 9% of surgeons said their relationship with the interventional cardiologist was disrupted. Two-thirds of vascular complications were managed by cardiac surgery, and only 6% of cardiac surgeons admitted were unfit to handle any vascular complications. CONCLUSIONS: In France, cardiac surgeons are becoming increasingly involved in TAVR procedures as an integral part of the Heart Team.
- Open Access
- 7 September 2024
- Published by Elsevier in JTCVS Open
- Vol. 22, 25-35
Multimodal analgesia with parasternal plane block protocol within an enhanced recovery after cardiac surgery program decreases opioid use
- 7 September 2024
- Published by Elsevier in JTCVS Open
- Vol. 22, 25-35
Open AccessMultimodal analgesia with parasternal plane block protocol within an enhanced recovery after cardiac surgery program decreases opioid use
- 14 May 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (10) , 1138-1154
Activated factor X stimulates atrial endothelial cells and tissues to promote remodelling responses through AT1R/NADPH oxidases/SGLT1/2
Aims: Atrial fibrillation (AF), the most common cardiac arrhythmia favouring ischemic stroke and heart failure involves left atrial remodelling, fibrosis and a complex interplay between cardiovascular risk factors. This study examined whether activated factor X (FXa) induces pro-remodelling and pro-fibrotic responses in atrial endothelial cells (AECs) and human atrial tissues and determined the underlying mechanisms. Methods and results: AECs collected from porcine hearts and human right atrial appendages (RAA) from patients undergoing heart surgery. Protein expression levels were assessed by Western blot and immunofluorescence staining, mRNA levels by RT-qPCR, formation of reactive oxygen species (ROS) and NO using fluorescent probes, thrombin and angiotensin II generation by specific assays, fibrosis by Sirius red staining and senescence by senescence-associated beta-galactosidase (SA-β-gal) activity. In AECs, FXa increased ROS formation, senescence (SA-β-gal activity, p53, p21), angiotensin II generation and the expression of pro-inflammatory (VCAM-1, MCP-1), pro-thrombotic (tissue factor), pro-fibrotic (TGF-β and collagen-1/3a) and pro-remodelling (MMP-2/9) markers whereas eNOS levels and NO formation were reduced. These effects were prevented by inhibitors of FXa but not thrombin, protease-activated receptors antagonists (PAR-1/2) and inhibitors of NADPH oxidases, ACE, AT1R, SGLT1/SGLT2. FXa also increased expression levels of ACE1, AT1R, SGLT1/2 proteins which were prevented by SGLT1/2 inhibitors. Human RAA showed tissue factor mRNA levels that correlated with markers of endothelial activation, pro-remodelling and pro-fibrotic responses and SGLT1/2 mRNA levels. They also showed protein expression levels of ACE1, AT1R, p22phox, SGLT1/2, and immunofluorescence signals of nitrotyrosine and SGLT1/2 colocalized with those of CD31. FXa increased oxidative stress levels which were prevented by inhibitors of the AT1R/NADPH oxidases/SGLT1/2 pathway. Conclusion: FXa promotes oxidative stress triggering premature endothelial senescence and dysfunction associated with pro-thrombotic, pro-remodelling and pro-fibrotic responses in AECs and human RAA involving the AT1R/NADPH oxidases/SGLT1/2 pro-oxidant pathway. Targeting this pathway may be of interest to prevent atrial remodelling and the progression of atrial fibrillation substrate.
- 14 May 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (10) , 1138-1154
Activated factor X stimulates atrial endothelial cells and tissues to promote remodelling responses through AT1R/NADPH oxidases/SGLT1/2
Aims: Atrial fibrillation (AF), the most common cardiac arrhythmia favouring ischemic stroke and heart failure involves left atrial remodelling, fibrosis and a complex interplay between cardiovascular risk factors. This study examined whether activated factor X (FXa) induces pro-remodelling and pro-fibrotic responses in atrial endothelial cells (AECs) and human atrial tissues and determined the underlying mechanisms. Methods and results: AECs collected from porcine hearts and human right atrial appendages (RAA) from patients undergoing heart surgery. Protein expression levels were assessed by Western blot and immunofluorescence staining, mRNA levels by RT-qPCR, formation of reactive oxygen species (ROS) and NO using fluorescent probes, thrombin and angiotensin II generation by specific assays, fibrosis by Sirius red staining and senescence by senescence-associated beta-galactosidase (SA-β-gal) activity. In AECs, FXa increased ROS formation, senescence (SA-β-gal activity, p53, p21), angiotensin II generation and the expression of pro-inflammatory (VCAM-1, MCP-1), pro-thrombotic (tissue factor), pro-fibrotic (TGF-β and collagen-1/3a) and pro-remodelling (MMP-2/9) markers whereas eNOS levels and NO formation were reduced. These effects were prevented by inhibitors of FXa but not thrombin, protease-activated receptors antagonists (PAR-1/2) and inhibitors of NADPH oxidases, ACE, AT1R, SGLT1/SGLT2. FXa also increased expression levels of ACE1, AT1R, SGLT1/2 proteins which were prevented by SGLT1/2 inhibitors. Human RAA showed tissue factor mRNA levels that correlated with markers of endothelial activation, pro-remodelling and pro-fibrotic responses and SGLT1/2 mRNA levels. They also showed protein expression levels of ACE1, AT1R, p22phox, SGLT1/2, and immunofluorescence signals of nitrotyrosine and SGLT1/2 colocalized with those of CD31. FXa increased oxidative stress levels which were prevented by inhibitors of the AT1R/NADPH oxidases/SGLT1/2 pathway. Conclusion: FXa promotes oxidative stress triggering premature endothelial senescence and dysfunction associated with pro-thrombotic, pro-remodelling and pro-fibrotic responses in AECs and human RAA involving the AT1R/NADPH oxidases/SGLT1/2 pro-oxidant pathway. Targeting this pathway may be of interest to prevent atrial remodelling and the progression of atrial fibrillation substrate.